Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa

Clinical Infectious Diseases

Volumn 50, Issue 11, 2010, Pages 1532-1538

  Makadzange, Azure T ^a,c   Ndhlovu, Chiratidzo E ^c   Takarinda, Kudakwashe ^c   Reid, Michael ^c   Kurangwa, Magna ^c   Gona, Philimon ^b   Hakim, James G ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Boston University   (United States)

^c UNIVERSITY OF ZIMBABWE   (Zimbabwe)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; LAMIVUDINE; NEVIRAPINE; STAVUDINE;

ADULT; AFRICA; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYPTOCOCCAL MENINGITIS; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

ADULT; ANTI-HIV AGENTS; ANTIFUNGAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; FLUCONAZOLE; HIV INFECTIONS; HUMANS; MALE; MENINGITIS, CRYPTOCOCCAL; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; ZIMBABWE;

EID: 77951840743     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/652652     Document Type: Article

References (32)

1. Jarvis JN, Boulle A, Loyse A, et al. High ongoing burden ofcryptococcal disease in Africa despite antiretroviral roll out. AIDS 2009; 23(9): 1182-1183.
2. Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, Harrison TS. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 2009;48(7):856-862.
3. 3. Heyderman RS, Gangaidzo IT, Hakim JG, et al. Cryptococcal meningitis in human immunodeficiency virus-infected patients in Harare, Zimbabwe. Clin Infect Dis 1998;26(2):284-289. (Pubitemid 28083935)
4. Hakim JG, Gangaidzo IT, Heyderman RS, et al. Impact of HIV infection on meningitis in Harare, Zimbabwe: a prospective study of 406 predominantly adult patients. AIDS 2000; 14(10):1401-1407.
5. 5. French N, Gray K, Watera C, et al. Cryptococcal infection, in a cohort of HIV-1-infected Ugandan adults. AIDS 2002; 16(7):1031-1038. (Pubitemid 34499426)
6. Lara-Peredo O, Cuevas LE, French N, Bailey JW, Smith DH. Cryptococcal infection in an HIV-positive Ugandan population. J Infect 2000; 41(2):195.
7. Longley N, Muzoora C, Taseera K, et al. Dose response effect of highdose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis 2008;47(12):1556-1561.
8. 8. Mwaba P, Mwansa J, Chintu C, et al. Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad Med J 2001;77(914):769-773. (Pubitemid 33116512)
9. Schaars CF, Meintjes GA, Morroni C, Post FA, Maartens G. Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole. BMC Infect Dis 2006; 6:118.
10. 10. Menichetti F, Fiorio M, Tosti A, et al. High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996; 22(5):838-840. (Pubitemid 26255605)
11. Berry AJ, Rinaldi MG, Graybill JR. Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. Antimicrob Agents Chemother 1992;36(3):690-692.
12. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000;30(4):710-718.
13. Larsen RA, Leal MA, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial. Ann Intern Med 1990;113(3):183-187.
14. van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997;337(1): 15-21.
15. 15. Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis 2000;30(1):47-54. (Pubitemid 30067061)
16. Schutte CM, Van der Meyden CH, Magazi DS. The impact of HIV on meningitis as seen at a South African Academic Hospital (1994 to 1998). Infection 2000;28(1):3-7.
17. 17. McCarthy KM, Morgan J, Wannemuehler KA, et al. Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence. AIDS 2006;20(17):2199-2206. (Pubitemid 44684711)
18. 18. Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007;45(1):76-80. (Pubitemid 46984619)
19. 19. Bicanic T, Wood R, Bekker LG, Darder M, Meintjes G, Harrison TS. Antiretroviral roll-out, antifungal roll-back: access to treatment for cryptococcal meningitis. Lancet Infect Dis 2005;5(9):530-531. (Pubitemid 41196749)
20. Sloan D, Dlamini S, Paul N, Dedkoat M. Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings. Cochrane Database Syst Rev 2008(4):CD005647.
21. Pfizer. Diflucan Partnership: Pfizer: the world's largest research-based pharmaceutical company. http://www.pfizer.com/responsibility/global-health/ diflucan-partnership-program.jsp. Accessed 22 January 2010.
22. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009; 4(5): e5575.
23. Bisson GP, Nthobatsong R, Thakur R, et al. The use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitis in adults in Botswana. J Acquir Immune Defic Syndr 2008;49(2):227-229.
24. 24. Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents: drug interactions of clinical significance. Drug Saf 1998; 18(2):83-97. (Pubitemid 28080742)
25. Geel J, Pitt J, Orrell C, Van Dyk M, Wood R. The effect of fluconazole on nevirapine pharmacokinetics. AIDS 2004; 1:369. Abstract TuPeB4606.
26. Siddiqui AA, Brouwer AE, Wuthiekanun V, et al. IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis. J Immunol 2005;174(3):1746-1750.
27. Bourgarit A, Carcelain G, Samri A, et al. Tuberculosis-associated immune restoration syndrome in HIV-1-infected patients involves tuberculinspecific CD4 Th1. cells and KIR-negative gammadelta T cells. J Immunol 2009; 183(6):3915-3923.
28. Meintjes G, Wilkinson KA, Rangaka MX, et al. Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med 2008; 178(10):1083-1089.
29. Murdoch DM, Suchard MS, Venter WD, et al. Polychromatic immunophenotypic characterization of T cell profiles among HIV-infected patients experiencing immune reconstitution inflammatory syndrome (IRIS). AIDS Res Ther 2009;6:16.
30. Salim Abdool Karim KN, Grobler A, Padayatchi N, et al. Initiating ART during TB treatment significantly increases survival: results of a randomized controlled clinical trial in TB/HIV-co-infected patients in South Africa. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 2009. Abstract 36a.
31. Bii CC, Makimura K, Abe S, et al. Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya. Mycoses 2007;50(1):25-30.
32. Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007:10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2009;47(1):117-123.